Why some skin cancers defy immunotherapy—and how to fight back
A study has revealed why some patients don’t respond to immune checkpoint blockade (ICB) therapy for solid cancer tumors and identifies a new combination treatment.
Medical Xpress
Pre-surgical combination therapy boosts survival in patients with rare thyroid cancer
A pre-surgical combination therapy including pembrolizumab plus dabrafenib and trametinib (DTP) significantly improved survival in patients with rare BRAF V600E-mutated anaplastic thyroid cancer (BRAFm-ATC) compared with historical controls, according …
Antibody-drug combination outperforms standard treatment of advanced triple-negative breast cancer
In patients with an aggressive form of breast cancer, treatment with the antibody-drug conjugate sacituzumab govitecan plus pembrolizumab resulted in durable responses with improved progression free survival compared to the current standard treatment. …
Dual-target CAR T cell therapy slows growth of aggressive brain cancer
A dual-target CAR T cell therapy approach shows promise for slowing tumor growth in a notoriously aggressive and fast-growing brain cancer. Tumors became smaller after the experimental CAR T cell therapy in nearly two-thirds of patients.
Combination therapy extends survival in advanced skin cancer, trial finds
In patients with an advanced type of skin cancer called cutaneous squamous cell carcinoma (cSCC), those who received the combination of the immunotherapy drug avelumab and targeted agent cetuximab had almost four times longer median progression-free su…
What is mantle cell lymphoma? The ‘rare and fast-moving’ cancer explained
Beloved Australian actor, Magda Szubanski, has revealed she’s been diagnosed with a “very rare, very aggressive, very serious” blood cancer called mantle cell lymphoma.
Antibody-mediated protection mechanism expands tuberculosis treatment options
Researchers at the Ragon Institute have made a significant discovery about how antibodies can directly enhance the body’s ability to fight Mycobacterium tuberculosis (Mtb), the bacteria responsible for tuberculosis (TB). Despite decades of research, TB…
HER3-targeted antibody-drug conjugate shows promise for treatment-resistant solid tumors
A new targeted cancer drug, DB-1310, is showing early signs of effectiveness in patients with advanced solid tumors that have not responded to standard treatments, particularly those with EGFR-mutant non-small cell lung cancer (NSCLC), according to res…
Innovative immunotherapy shows promise against aggressive T cell cancers
A new type of immunotherapy that targets aggressive blood cancers shows promising results alongside manageable side effects, according to the results of an international Phase I/II clinical trial led by researchers at Washington University School of Me…
Food as friend, not foe—study maps cellular network that enables safe food consumption through oral tolerance
If we have an allergy to peanuts, strawberries or dairy, we are quick to blame our immune systems. But when we enjoy a diverse diet without any adverse reaction, we generally don’t realize that this is also the immune system’s doing.